IGF1R and neoplasm: Importantly, our findings highlight the therapeutic value of dual targeting this axis-combining the IGF1R inhibitor linsitinib with surufatinib significantly enhances anti-tumor effects in preclinical models, underscoring a synergistic strategy to overcome resistance and achieve deeper, more sustained responses (Fig. 7).